AzTrials
AzTrials

Influenza A and BNCT03366402

Sub Populations of Immune Cells in Influenza A and B Patients

An observational study of Influenza A and B, run by Dr. Nechama Sharon at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days). Read more about this study

Who is it for?
Ages Up to 16 years
Conditions the study is for
Influenza A and B
What is being tested?
RT-PCR H1N1
How many people
60 participants
Where
1 siteIsrael
Study dates
Jan 2017to May 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Children hospitalized at the pediatric department with signs and symptoms of flu.

Who may be able to join

  • Children aged 0-16
  • Have signed a written consent by parents or legal guardians
  • Signs and symptoms of flu

Who cannot join

  • Immune system disease

Trial locations and contacts

1 site in 1 country.

Nechama Sharon, Dr. contact

+972-9-8604738

nsharon@laniado.org.il

Israel1 site, 1 recruiting
  • Sharon Nechama, Laniado Hospital

    Netanya

    Nechama Sharone, MD, 972-544303356, nsharon@laniado.org.il

    Nechama Sharon, MD

    Recruiting

Other trials in Israel

About this study

This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days).

The participants are children that are hospitalized in the Laniado hospital pediatric department.

Read the detailed description

Background:

In late March and early April 2009 an outbreak of a novel influenza virus designated A/H1N1 influenza (popularly known as swine flu) was reported in Mexico, with subsequent cases observed in many countries, leading to the declaration by the World Health Organization of a worldwide pandemic.

The first case of influenza A/H1N1 in Israel was diagnosed at the end of April 2009 at Laniado Hospital in a young man returning from Mexico.

Influenza A/H1N1 (Swine flu) carries a relatively high morbidity, particularly in young patients. Early identification would enable prompt initiation of therapy, thereby improving outcomes.

In 2009, during the H1N1 pandemic in Israel, a research was conducted in our department of pediatrics. The researchers Sharon et al. (1) have compared a group of 53 children infected with Influenza A H1N1, with a group of 53 children that presented with flu symptoms but were found negative for the virus. This comparison demonstrated a significant reduction in lymphocyte count during the acute phase of the disease (days 1-3) with resolution on day 7 (6-9) as well as reduction in the neutrophil count on day 5 from the onset of high fever with subsequent resolution 2-4 days later (days 7-10). This phenomenon was not observed in the patients that were not infected with the H1N1 virus. Similar results were reported by Cao and co-authors (2) that observed it in both pediatric and adult patients. Lewis at al suggested that the lymphopenia is mainly due to reduction in T cells and to a lesser extent in B cells (3). The lymphopenia typical of influenza A H3N3 during acute illness was shown to be due to a reduction in both T and B cells without alteration in the CD4:CD8 ratio. This is in contrast to the findings of Cao et al. (2) who noted an abnormal CD4:CD8 ratio in half of those who were positive for A H1N1. One of the possible explanations as proposed by Nichols and Collaborators (4) is that early lymphopenia and the later neutropenia in the influenza infected patients may represent migration of these cells from the circulation to the infected respiratory tract as a consequence of infection. Goals of our research To quantify the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.

Study methods The subjects of the study were children that were hospitalized at our department with signs and symptoms of flu. The parents or legal guardians of the participants have signed a written consent. At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.

Laboratory technique:

Cellular markers were assessed by flow cytometry. Cell staining was performed on single cell suspensions using pre-cooled PBS in 5 ml FACS tubes. Washing steps were performed by centrifugation for 5min, 300 g, 5°C, brake 5 after which supernatants were completely pipetted off and cell pellets (typically containing 0.2-1.0×106 cells) were re-suspended in 100 μl PBS (without Ca++and Mg++) supplemented with 0.5% bovine serum albumin, stained with specific fluorochrome-conjugated anti-human antibodies or isotype-matched non-specific controls and incubated in the refrigerator 2-8°C for 30 min. After incubation, cells were washed by centrifugation and re-suspended in 0.25-0.5 ml cold PBS.

Cells tested were stained with mouse monoclonal antibodies for CD45-FITC, CD45-PE a pan leukocyte marker, T Cell marker CD3-PE CD8-FITC, T helper cells CD4-FITC, CD8-PE, Natural killer (NK) cell marker CD56-PE, monocyte marker CD31-FITC and B cell marker CD19-PE.

Emission compensation was done by positive control tubes containing cells that were stained with CD45-FITC or CD45-PE; Dead cells were excluded by staining with 7-aminoactinomycin D, only un-stained viable cells were analyzed. At least 10,000 cellular events per sample were analyzed using the CellQuest Pro or FlowJo software. Percentages of isotype control antibody staining, not exceeding 1% stained cells, were used to set the 'positive'staining gates, and were deduced from the specific antibody results. The results are expressed as the percentage of stained cells.

Being tested
RT-PCR H1N1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RT-PCR H1N1Diagnostic test

    At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.

Study groups in NCT03366402
Study groupRoleWhat they receive
Influenza ANot described
Receives: Diagnostic Test: RT-PCR H1N1
Influenza BNot described
Receives: Diagnostic Test: RT-PCR H1N1

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.

    The identification and quantification of the different cell types are performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.

    The primary outcome measure was defined as the absolute number of lymphocytes of each sub population. Thus, farther allowing us to follow both absolute numbers and relative percentage of the whole.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2017
  2. Study startJan 2017
  3. Primary completionJan 2020 (estimated)
  4. Study completionMay 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03366402
Sponsor's protocol ID
0015-16-LND
Status last verified
Jan 2018
First submitted
16 Nov 2017
Last updated
4 Jan 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Influenza A and B, run by Dr. Nechama Sharon at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nechama Sharon, Dr. (+972-9-8604738, nsharon@laniado.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1. (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in